2016
Oral Dimethyl Fumarate in Children With Multiple Sclerosis: A Dual-Center Study
Makhani N, Schreiner T. Oral Dimethyl Fumarate in Children With Multiple Sclerosis: A Dual-Center Study. Pediatric Neurology 2016, 57: 101-104. PMID: 26996405, DOI: 10.1016/j.pediatrneurol.2016.01.010.Peer-Reviewed Original ResearchConceptsOral dimethyl fumarateMultiple sclerosisDimethyl fumarateSide effectsFirst-line injectable therapiesBrain magnetic resonance imagingAbnormal liver transaminasesDual-Center ExperienceUsual adult doseMonths of therapyNew T2 lesionsFirst-line therapyCommon side effectsMagnetic resonance imaging (MRI) parametersPediatric multiple sclerosisDual-center studyChildren 18 yearsFormal clinical trialsMagnetic resonance imagingLiver transaminasesDisability scoresLaboratory abnormalitiesOral medicationsRelapse rateRetrospective review
2009
Cyclophosphamide therapy in pediatric multiple sclerosisSYMBOLSYMBOL
Makhani N, Gorman MP, Branson HM, Stazzone L, Banwell BL, Chitnis T. Cyclophosphamide therapy in pediatric multiple sclerosisSYMBOLSYMBOL. Neurology 2009, 72: 2076-2082. PMID: 19439723, PMCID: PMC2923592, DOI: 10.1212/wnl.0b013e3181a8164c.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsAge of OnsetChildCyclophosphamideDisease ProgressionDrug Administration ScheduleDrug ResistanceFemaleGlatiramer AcetateHumansImmunosuppression TherapyImmunosuppressive AgentsInterferon-betaMaleMitoxantroneMultiple SclerosisPeptidesRetrospective StudiesSecondary PreventionSex DistributionTreatment OutcomeConceptsMultiple sclerosisTreatment of childrenInduction therapyMaintenance therapyTreatment initiationDisability Status Scale scoreAggressive multiple sclerosisFirst-line therapyRetrospective chart reviewMajority of patientsStatus Scale scoreCyclophosphamide therapyChart reviewDisability scoresMost patientsMulticenter experienceMultiple relapsesRelapse ratePatient selectionTransient alopeciaBladder carcinomaTreatment administrationCyclophosphamideSide effectsScale score